|
Characteristics
|
N (%)
|
|---|
|
Age (yr), median (range)
|
4
|
|
<1
|
0
|
|
1-9
|
136 (82.9)
|
|
≥10
|
28 (17.1)
|
|
Gender
| |
|
Male
|
104 (63.4)
|
|
Female
|
60 (36.6)
|
|
WBC (109/L)
| |
|
<50
|
136 (82.9)
|
|
≥50
|
28 (17.1)
|
|
Treatment group
| |
|
SR
|
62 (37.8)
|
|
MR
|
81 (49.4)
|
|
HR
|
21 (12.8)
|
|
Fusion genes
| |
|
TEL-AML1
|
41 (25.0)
|
|
E2A-PBX1
|
16 (9.8)
|
|
BCR-ABL
|
8 (4.9)
|
|
MLL-AF4
|
1 (0.6)
|
|
CNS involvement
|
2 (1.2)
|
|
Event
| |
|
Relapse
|
16 (9.8)
|
|
Isolated BM
|
13 (7.9)
|
|
Isolated CNS
|
1 (0.6)
|
|
Isolated testis
|
2 (1.2)
|
|
Death*
|
4 (2.4)
|
|
Prednisone response
| |
|
Good
|
162 (98.8)
|
|
Poor
|
2 (1.2)
|
- BCP-ALL, B-cell precursor ALL; WBC, white blood cell count; SR, standard-risk; MR, medium-risk; HR, high-risk; BM, bone marrow; CNS, central nervous system. *4 patients died of severe infections during induction.
